Combined Immunotherapies Show Promise in Metastatic Melanoma

The results of two studies indicate that combining antibodies against the programmed death 1 (PD-1) receptor with an antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) improved treatment outcomes for patients with advanced melanoma, without a significant increase in adverse events.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news